TL;DR: The Centers for Medicare & Medicaid Services modified NCD 92, the National Coverage Determination governing closed-loop blood glucose control device (CBGCD) coverage under Medicare, with an effective date of March 7, 2026. Here's what billing teams need to know.
This CMS closed-loop blood glucose control device coverage policy applies exclusively to inpatient hospital billing for short-term management of insulin-dependent diabetics in crisis. The policy does not list specific CPT or HCPCS codes—a gap your billing team needs to address before claims go out. If you bill for hospital bedside diabetes management devices, this policy update belongs on your radar now.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Closed-Loop Blood Glucose Control Device (CBGCD) |
| Policy Code | NCD 92 |
| Change Type | Modified |
| Effective Date | March 7, 2026 |
| Impact Level | Medium |
| Specialties Affected | Inpatient Hospital, Endocrinology, Surgery, Obstetrics, Trauma/Critical Care |
| Key Action | Verify your facility's billing codes for CBGCD before submitting inpatient claims — NCD 92 lists no specific CPT or HCPCS codes, so consult your MAC for current coding guidance |
CMS Closed-Loop Blood Glucose Control Device Coverage Criteria and Medical Necessity Requirements 2026
NCD 92 in the Medicare system governs whether a closed-loop blood glucose control device qualifies for Medicare reimbursement in an inpatient hospital setting. The coverage policy is narrow by design. CMS covers the CBGCD only for short-term management of insulin-dependent diabetics in crisis situations, inside a hospital inpatient setting, and only when use is directed by specially trained medical personnel.
That phrase "crisis situations" is doing a lot of work here. The policy specifies three primary clinical contexts: trauma, labor and delivery, and surgery. These are situations where blood sugar levels swing widely and fast, and where standard insulin management isn't sufficient.
The medical necessity bar is real. The CBGCD isn't covered for routine inpatient glucose monitoring or standard diabetes management during a typical admission. The device is designed for the acute, unstable patient — someone whose glucose is swinging hard enough that continuous automated correction via insulin or dextrose infusion is clinically warranted.
The device itself has four components: a rapid on-line glucose analyzer, a computer with a controller for insulin or dextrose infusion, a multi-channel infusion system, and a printer that records continuous glucose values and cumulative infusion totals. All four components work together as a system. This is not a standalone glucometer or a simple insulin drip — it's an integrated bedside system.
Use is generally limited to a 24- to 48-hour window. CMS is explicit about this. The limitation exists because of documented complications — sepsis, thromboses, and the device's nonportability. Your documentation needs to reflect why the device was used, for how long, and who was directing its use.
Prior authorization requirements are not explicitly addressed within NCD 92 itself. That doesn't mean prior authorization isn't required at the plan level or under a specific Medicare Advantage contract. If your facility is billing Medicare Advantage, check the plan's specific prior auth requirements before the claim goes out. Don't assume national coverage policy silence on prior auth means blanket approval.
CMS Closed-Loop Blood Glucose Control Device Exclusions and Non-Covered Indications
The policy draws a clear line: this device is for Type I (insulin-dependent) diabetics only. Type II diabetic patients are not mentioned as covered indications. Billing a CBGCD claim for a Type II diabetic patient will put you at risk for a claim denial on medical necessity grounds.
Outpatient use is also not covered. The benefit category is inpatient hospital services only. If your facility uses this device in an observation status encounter or an outpatient surgical setting, the NCD 92 coverage policy does not apply — and Medicare will not reimburse under this determination.
Use beyond the 48-hour window requires strong clinical justification. The policy sets the 24- to 48-hour period as the expected range. Extended use without documented medical necessity creates audit exposure. Your clinical documentation needs to explain any deviation from that timeline.
Finally, use without specially trained medical personnel directing the device is not covered. This isn't just a clinical safety standard — it's a coverage requirement. Lack of documented physician oversight is a denial waiting to happen.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Short-term management of insulin-dependent (Type I) diabetic in crisis — inpatient | Covered | Not specified in NCD 92 | Must be directed by specially trained medical personnel; limited to 24–48 hours |
| Acute glucose instability during trauma | Covered | Not specified in NCD 92 | Crisis situation qualifier applies |
| Acute glucose instability during labor and delivery | Covered | Not specified in NCD 92 | Crisis situation qualifier applies |
| Acute glucose instability during surgery | Covered | Not specified in NCD 92 | Crisis situation qualifier applies |
| Routine inpatient glucose management | Not Covered | Not specified in NCD 92 | Does not meet medical necessity criteria under NCD 92 |
| Outpatient or observation-status use | Not Covered | Not specified in NCD 92 | Benefit category is inpatient hospital services only |
| Use in Type II (non-insulin-dependent) diabetics | Not Covered | Not specified in NCD 92 | Policy specifies insulin-dependent diabetes mellitus only |
| Use beyond 48 hours without additional justification | At Risk | Not specified in NCD 92 | Document medical necessity carefully; audit exposure increases |
| Use without specially trained medical personnel | Not Covered | Not specified in NCD 92 | Coverage requires physician direction and continuous observation |
CMS Closed-Loop Blood Glucose Control Device Billing Guidelines and Action Items 2026
NCD 92 as modified is in effect as of March 7, 2026. Your facility's billing team should have already taken the steps below. If you haven't, do them now.
| # | Action Item |
|---|---|
| 1 | Contact your Medicare Administrative Contractor (MAC) for current coding guidance. NCD 92 does not list specific CPT or HCPCS codes. That's not unusual for older NCDs, but it means your MAC controls the coding interpretation. Call your MAC's provider outreach line or check their website for any associated local coverage determination (LCD) or coding article that covers CBGCD claims. Don't submit claims without knowing what codes your MAC expects. |
| 2 | Audit your clinical documentation templates for CBGCD use. Your documentation needs to capture four things: (a) patient has insulin-dependent (Type I) diabetes mellitus, (b) a qualifying crisis situation (trauma, surgery, or labor and delivery), (c) direction and continuous observation by specially trained medical personnel, and (d) duration of use within the 24- to 48-hour expected window or with documented justification for extension. If your current templates don't capture all four, update them before the next inpatient case. |
| 3 | Verify patient status before billing. The CBGCD coverage policy applies to inpatient hospital services only. If the patient was under observation status when the device was used, NCD 92 does not cover the claim. Flag these cases for your compliance officer or billing consultant before they hit the claim queue. |
| 4 | Check Medicare Advantage contract requirements separately. NCD 92 is a national fee-for-service determination. Medicare Advantage plans follow NCD 92 as a floor but can impose additional restrictions — including prior authorization requirements that don't exist in the NCD. Pull your top Medicare Advantage payer contracts and confirm CBGCD billing guidelines for each before the next billing cycle. |
| 5 | Train your charge capture team on the clinical specificity required. "Diabetes management device" is not enough. Charge capture for CBGCD claims needs to reflect the specific crisis indication, the inpatient status, and the trained personnel requirement. Vague charge descriptions are a direct path to a claim denial. If your charge capture workflow doesn't prompt for this level of specificity, that's a process gap worth fixing now. |
| 6 | Review any open or pending CBGCD claims for compliance with the updated policy. If you have claims in process that were captured under older documentation standards, review them before submission. The effective date of March 7, 2026 means claims with dates of service on or after that date are subject to the modified coverage policy. Don't let stale documentation practices follow you into the new policy period. |
If you're uncertain how this policy applies to your facility's specific case mix — particularly if you have a high volume of surgical or obstetric patients with diabetes — talk to your compliance officer before your next billing run. The coverage criteria here are specific enough that a small documentation gap can flip a covered claim into a denial.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Closed-Loop Blood Glucose Control Device Under NCD 92
Important Note on Codes
NCD 92 does not list specific CPT or HCPCS codes in the policy document. This is a known gap with older National Coverage Determinations that were written before current coding structures were fully developed.
Your next step is to contact your MAC directly. Your MAC may have a companion local coverage determination (LCD) or billing article that assigns specific codes to CBGCD claims in your region. Do not submit claims without confirming the expected code set with your MAC.
What to Ask Your MAC
When you contact your MAC, ask specifically:
- What CPT or HCPCS code should be used to bill for a closed-loop blood glucose control device in an inpatient hospital setting?
- Is there an active LCD or billing article that supplements NCD 92 for CBGCD claims?
- Are there diagnosis codes (ICD-10-CM) required to support medical necessity on the claim?
- Are there any additional documentation requirements beyond those stated in NCD 92?
Your MAC's answer will determine your billing guidelines for this device. Do not rely on codes used at other facilities or pulled from older coding references without verifying current applicability.
Diagnosis Context (from Policy Summary)
While NCD 92 does not list specific ICD-10-CM codes, the clinical criteria point clearly to insulin-dependent diabetes mellitus (Type I) with an acute complication or crisis. When your MAC confirms the required diagnosis codes, you'll be looking for ICD-10 codes in the E10 category (Type 1 diabetes mellitus) with applicable complication or severity qualifiers. Confirm the exact codes with your MAC and your coding team.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.